Total Payments
$707.82
2024 Payments
$132.85
Companies
10
Transactions
20
Medicare Patients
2,772
Medicare Billing
$327,081
Payment Breakdown by Category
Food & Beverage$634.52 (89.6%)
Education$73.30 (10.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $634.52 | 19 | 89.6% |
| Education | $73.30 | 1 | 10.4% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $143.86 | 8 | $0 (2024) |
| Intercept Pharmaceuticals, Inc. | $115.64 | 1 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $114.10 | 1 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $103.13 | 1 | $0 (2020) |
| Synergy Pharmaceuticals Inc | $73.30 | 1 | $0 (2018) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $45.44 | 3 | $0 (2021) |
| Amgen Inc. | $33.23 | 1 | $0 (2022) |
| US Endoscopy | $28.11 | 2 | $0 (2018) |
| Boston Scientific Corporation | $27.87 | 1 | $0 (2019) |
| Shire North American Group Inc | $23.14 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $132.85 | 2 | Intercept Pharmaceuticals, Inc. ($115.64) |
| 2023 | $45.58 | 2 | AbbVie Inc. ($45.58) |
| 2022 | $47.95 | 2 | Amgen Inc. ($33.23) |
| 2021 | $175.75 | 5 | E.R. Squibb & Sons, L.L.C. ($114.10) |
| 2020 | $117.25 | 2 | Takeda Pharmaceuticals U.S.A., Inc. ($103.13) |
| 2019 | $72.19 | 3 | Boston Scientific Corporation ($27.87) |
| 2018 | $116.25 | 4 | Synergy Pharmaceuticals Inc ($73.30) |
All Payment Transactions
20 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 06/26/2024 | Intercept Pharmaceuticals, Inc. | OCALIVA (Drug) | Food and Beverage | In-kind items and services | $115.64 | General |
| Category: Hepatology / Gastroenterology | ||||||
| 04/18/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $17.21 | General |
| Category: IMMUNOLOGY | ||||||
| 12/05/2023 | AbbVie Inc. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $18.94 | General |
| Category: IMMUNOLOGY | ||||||
| 09/20/2023 | AbbVie Inc. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $26.64 | General |
| Category: IMMUNOLOGY | ||||||
| 10/13/2022 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $14.72 | General |
| Category: IMMUNOLOGY | ||||||
| 01/12/2022 | Amgen Inc. | AVSOLA (Biological) | Food and Beverage | In-kind items and services | $33.23 | General |
| Category: Inflammation | ||||||
| 12/07/2021 | E.R. Squibb & Sons, L.L.C. | ZEPOSIA (Drug) | Food and Beverage | Cash or cash equivalent | $114.10 | General |
| Category: Neuroscience | ||||||
| 11/17/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $16.10 | General |
| Category: IMMUNOLOGY | ||||||
| 11/17/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Gastroenterology | ||||||
| 10/20/2021 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.66 | General |
| Category: Gastroenterology | ||||||
| 09/21/2021 | AbbVie Inc. | HUMIRA (Biological) | Food and Beverage | In-kind items and services | $14.23 | General |
| Category: IMMUNOLOGY | ||||||
| 04/08/2020 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $14.12 | General |
| Category: GASTROENTEROLOGY | ||||||
| 02/27/2020 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $103.13 | General |
| 11/14/2019 | AbbVie, Inc. | Mavyret (Drug) | Food and Beverage | In-kind items and services | $21.18 | General |
| Category: Virology | ||||||
| 10/31/2019 | Boston Scientific Corporation | GENERAL ENDOCHOICE (Device) | Food and Beverage | In-kind items and services | $27.87 | General |
| Category: ENDOCHOICE | ||||||
| 01/15/2019 | Shire North American Group Inc | GATTEX (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: INTERNAL MEDICINE | ||||||
| 08/24/2018 | Synergy Pharmaceuticals Inc | Trulance (Drug) | Education | In-kind items and services | $73.30 | General |
| Category: Gastroenterology | ||||||
| 08/07/2018 | US Endoscopy | Padlock (Device), Infinity ERCP Sampling Device, Roth Net Retrievers | Food and Beverage | Cash or cash equivalent | $12.95 | General |
| Category: 78 Gastroenterology | ||||||
| 05/09/2018 | AbbVie, Inc. | Humira (Biological) | Food and Beverage | In-kind items and services | $14.84 | General |
| Category: Immunology | ||||||
| 02/13/2018 | US Endoscopy | Padlock (Device), Infinity ERCP Sampling Device, Roth Net Retrievers | Food and Beverage | Cash or cash equivalent | $15.16 | General |
| Category: 78 Gastroenterology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 743 | 843 | $381,344 | $86,413 |
| 2022 | 13 | 675 | 758 | $334,489 | $77,947 |
| 2021 | 14 | 733 | 861 | $349,722 | $92,739 |
| 2020 | 12 | 621 | 723 | $289,755 | $69,981 |
Total Patients
2,772
Total Services
3,185
Medicare Billing
$327,081
Procedure Codes
54
All Medicare Procedures & Services
54 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 189 | 242 | $66,550 | $23,756 | 35.7% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 77 | 112 | $21,220 | $10,798 | 50.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 48 | 50 | $65,000 | $10,724 | 16.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 83 | 84 | $20,504 | $8,656 | 42.2% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 71 | 71 | $19,525 | $5,758 | 29.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 69 | 70 | $67,190 | $5,539 | 8.2% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 52 | 54 | $64,800 | $5,129 | 7.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $12,950 | $4,526 | 35.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 12 | 12 | $10,380 | $2,268 | 21.9% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 29 | 33 | $4,285 | $2,076 | 48.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 14 | 15 | $5,250 | $2,071 | 39.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 23 | 24 | $4,560 | $1,795 | 39.4% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 11 | 11 | $10,450 | $1,663 | 15.9% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 16 | 16 | $2,800 | $1,026 | 36.7% |
| 91010 | Study of esophagus to assess movement | Facility | 2023 | 12 | 12 | $5,880 | $627.36 | 10.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 178 | 227 | $52,975 | $22,628 | 42.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 52 | 52 | $67,600 | $11,083 | 16.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 62 | 91 | $17,215 | $7,557 | 43.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 82 | 82 | $19,575 | $6,386 | 32.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 58 | 58 | $69,600 | $6,210 | 8.9% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 61 | 61 | $58,505 | $5,417 | 9.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 46 | 46 | $11,194 | $4,634 | 41.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 36 | 36 | $11,040 | $4,113 | 37.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 22 | 24 | $6,880 | $2,794 | 40.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 12 | 12 | $9,205 | $2,334 | 25.4% |
About Dr. Priyanka Sachdeva, MD
Dr. Priyanka Sachdeva, MD is a Gastroenterology healthcare provider based in Rydal, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/29/2006. The National Provider Identifier (NPI) number assigned to this provider is 1831255140.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Priyanka Sachdeva, MD has received a total of $707.82 in payments from pharmaceutical and medical device companies, with $132.85 received in 2024. These payments were reported across 20 transactions from 10 companies. The most common payment nature is "Food and Beverage" ($634.52).
As a Medicare-enrolled provider, Sachdeva has provided services to 2,772 Medicare beneficiaries, totaling 3,185 services with total Medicare billing of $327,081. Data is available for 4 years (2020–2023), covering 54 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Location Rydal, PA
- Active Since 12/29/2006
- Last Updated 09/05/2014
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1831255140
Products in Payments
- OCALIVA (Drug) $115.64
- ZEPOSIA (Drug) $114.10
- Trulance (Drug) $73.30
- SKYRIZI (Biological) $60.30
- XIFAXAN (Drug) $45.44
- AVSOLA (Biological) $33.23
- HUMIRA (Biological) $30.33
- Padlock (Device) $28.11
- GENERAL ENDOCHOICE (Device) $27.87
- GATTEX (Drug) $23.14
- Mavyret (Drug) $21.18
- RINVOQ (Biological) $17.21
- Humira (Biological) $14.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Rydal
Dr. Stuart Lubinski, M.d, M.D
Gastroenterology — Payments: $14,743
Gastroenterology $14,743
Dr. Cesar Delatorre, M.d, M.D
Gastroenterology — Payments: $2,877
Gastroenterology $2,877
Dr. Daniel Ringold, M.d, M.D
Gastroenterology — Payments: $2,130
Gastroenterology $2,130
Dr. Julia Binder, Md, MD
Gastroenterology — Payments: $1,099
Gastroenterology $1,099
Christina Brown, M.d, M.D
Gastroenterology — Payments: $1,072
Gastroenterology $1,072
Dr. Eric Goosenberg, M.d, M.D
Gastroenterology — Payments: $971.79
Gastroenterology $971.79